{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:03:29Z","timestamp":1786979009681,"version":"build-2736575974"},"publisher-location":"Cham","reference-count":129,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783319914381","type":"print"},{"value":"9783319914398","type":"electronic"}],"license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1007\/978-3-319-91439-8_7","type":"book-chapter","created":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T16:25:48Z","timestamp":1533140748000},"page":"133-168","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Ibrutinib"],"prefix":"10.1007","author":[{"given":"Andriani","family":"Charalambous","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark-Alexander","family":"Schwarzbich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Witzens-Harig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,2]]},"reference":[{"key":"7_CR1","doi-asserted-by":"crossref","unstructured":"Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, Kolibaba KS, Furman RR, Rodriguez S, Chang BY (2013) Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies. J Clin Oncol 31","DOI":"10.1200\/JCO.2012.42.7906"},{"issue":"11","key":"7_CR2","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2016-06-719294","volume":"129","author":"IE Ahn","year":"2017","unstructured":"Ahn IE, Underbayev C, Albitar A, Herman SEM, Tian X, Maric I, Arthur DC, Wake L, Pittaluga S, Yuan CM, Stetler-Stevenson M, Soto S, Valdez J, Nierman P, Lotter J, Xi L, Raffeld M, Farooqui M, Albitar M, Wiestner A (2017) Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood 129(11):1469\u20131479","journal-title":"Blood"},{"key":"7_CR3","first-page":"27","volume":"21","author":"B Arthurs","year":"2017","unstructured":"Arthurs B, Wunderle K, Hsu M, Kim S (2017) Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia. Respir Med Case Rep 21:27\u201329","journal-title":"Respir Med Case Rep"},{"issue":"1","key":"7_CR4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40959-017-0021-y","volume":"3","author":"A Asnani","year":"2017","unstructured":"Asnani A, Manning A, Mansour M, Ruskin J, Hochberg EP, Ptaszek LM (2017) Management of atrial fibrillation in patients taking targeted cancer therapies. Cardio-Oncology 3(1):2","journal-title":"Cardio-Oncology"},{"key":"7_CR5","unstructured":"Barbosa CC, DeAngelis LM, Grommes C (2017) Ibrutinib associated infections: a retrospective study. J Clin Oncol 35(15_suppl):e19020\u2013e19020"},{"issue":"22","key":"7_CR6","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1182\/blood.V128.22.234.234","volume":"128","author":"P Barr","year":"2016","unstructured":"Barr P, Robak T, Owen CJ, Tedeschi A, Bairey O, Bartlett NL, Burger J, Hillmen P, Coutre S, Devereux S, Grosicki S, McCarthy H, Li J, Simpson D, Offner F, Moreno C, Zhou C, Styles L, James DF, Kipps TJ, Ghia P (2016) Updated efficacy and safety from the phase 3 resonate-2 study: ibrutinib as first-line treatment option in patients 65 years and older with chronic lymphocytic leukemia\/small lymphocytic leukemia. Blood 128(22):234","journal-title":"Blood"},{"issue":"23","key":"7_CR7","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1182\/blood.V126.23.3301.3301","volume":"126","author":"JC Barrientos","year":"2015","unstructured":"Barrientos JC, Meyer N, Song X, Rai KR (2015) Characterization of atrial fibrillation and bleeding risk factors in patients with chronic lymphocytic leukemia (cll): a population-based retrospective cohort study of administrative medical claims data in the United States (US). Blood 126(23):3301","journal-title":"Blood"},{"issue":"10","key":"7_CR8","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/01.CIR.98.10.946","volume":"98","author":"EJ Benjamin","year":"1998","unstructured":"Benjamin EJ, Wolf PA, D\u2019Agostino RB, Silbershatz H, Kannel WB, Levy D (1998) Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 98(10):946\u2013952","journal-title":"Circulation"},{"issue":"9","key":"7_CR9","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.2011.36.9348","volume":"30","author":"S B\u00f6ttcher","year":"2012","unstructured":"B\u00f6ttcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G, Fink AM, B\u00fchler A, Zenz T, Wenger MK, Mendila M, Wendtner C-M, Eichhorst BF, D\u00f6hner H, Hallek MJ, Kneba M (2012) Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 30(9):980\u2013988","journal-title":"J Clin Oncol"},{"issue":"2\u20133","key":"7_CR10","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.clim.2005.10.007","volume":"118","author":"A Broides","year":"2006","unstructured":"Broides A, Yang W, Conley ME (2006) Genotype\/phenotype correlations in X-linked agammaglobulinemia. Clin Immunol 118(2\u20133):195\u2013200","journal-title":"Clin Immunol"},{"issue":"21","key":"7_CR11","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1182\/blood.V124.21.3331.3331","volume":"124","author":"JR Brown","year":"2014","unstructured":"Brown JR, Hillmen P, O\u2019Brien S, Barrientos JC, Reddy N, Coutre S, Tam C, Mulligan S, Jaeger U, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Thornton P, Caligaris-Cappio F, Delgado J, Montillo M, DeVos S, Moreno C, Pagel J, Burger JA, Chung D, Lin J, Gau L, Chang B, McGreivy J, James DF, Byrd JC (2014) Updated efficacy including genetic and clinical subgroup analysis and overall safety in the phase 3 resonate trial of ibrutinib versus ofatumumab in previously treated chronic lymphocytic leukemia\/small lymphocytic lymphoma. Blood 124(21):3331","journal-title":"Blood"},{"issue":"19","key":"7_CR12","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2014-09-585869","volume":"125","author":"JR Brown","year":"2015","unstructured":"Brown JR, Barrientos JC, Barr PM, Flinn IW, Burger JA, Tran A, Clow F, James DF, Graef T, Friedberg JW, Rai K, O\u2019Brien S (2015) The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. Blood 125(19):2915\u20132922","journal-title":"Blood"},{"issue":"6","key":"7_CR13","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1542\/peds.9.6.722","volume":"9","author":"OC Bruton","year":"1952","unstructured":"Bruton OC (1952) Agammaglobulinemia. Pediatrics 9(6):722\u2013728","journal-title":"Pediatrics"},{"issue":"10","key":"7_CR14","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(14)70335-3","volume":"15","author":"JA Burger","year":"2014","unstructured":"Burger JA, Keating MJ, Wierda WG, Hartmann E, Hoellenriegel J, Rosin NY, de Weerdt I, Jeyakumar G, Ferrajoli A, Cardenas-Turanzas M, Lerner S, Jorgensen JL, Nogueras-Gonz\u00e1lez GM, Zacharian G, Huang X, Kantarjian H, Garg N, Rosenwald A, O\u2019Brien S (2014) Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol 15(10):1090\u20131099","journal-title":"Lancet Oncol"},{"issue":"25","key":"7_CR15","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","volume":"373","author":"JA Burger","year":"2015","unstructured":"Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O\u2019Dwyer M, Hellmann A, Schuh A, Siddiqi T, Polliack A, Tam CS, Suri D, Cheng M, Clow F, Styles L, James DF, Kipps TJ (2015) Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 373(25):2425\u20132437","journal-title":"N Engl J Med"},{"key":"7_CR16","doi-asserted-by":"crossref","unstructured":"Burger JA, Landau DA, Taylor-Weiner A, Bozic I, Zhang H, Sarosiek K, Wang L, Stewart C, Fan J, Hoellenriegel J, Sivina M, Dubuc AM, Fraser C, Han Y, Li S, Livak KJ, Zou L, Wan Y, Konoplev S, Sougnez C, Brown JR, Abruzzo LV, Carter SL, Keating MJ, Davids MS, Wierda WG, Cibulskis K, Zenz T, Werner L, Cin PD, Kharchencko P, Neuberg D, Kantarjian H, Lander E, Gabriel S, O\u2019Brien S, Letai A, Weitz DA, Nowak MA, Getz G, Wu CJ (2016) Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat commun 7:11589","DOI":"10.1038\/ncomms11589"},{"issue":"2","key":"7_CR17","doi-asserted-by":"crossref","first-page":"e89904","DOI":"10.1172\/jci.insight.89904","volume":"2","author":"JA Burger","year":"2017","unstructured":"Burger JA, Li KW, Keating MJ, Sivina M, Amer AM, Garg N, Ferrajoli A, Huang X, Kantarjian H, Wierda WG, O\u2019Brien S, Hellerstein MK, Turner SM, Emson CL, Chen SS, Yan XJ, Wodarz D, Chiorazzi N (2017) Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib. JCI Insight 2(2):e89904","journal-title":"JCI Insight"},{"issue":"1","key":"7_CR18","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","volume":"369","author":"JC Byrd","year":"2013","unstructured":"Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Sukbuntherng J, Chang BY, Clow F, Hedrick E, Buggy JJ, James DF, O\u2019Brien S (2013) Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369(1):32\u201342","journal-title":"N Engl J Med"},{"issue":"3","key":"7_CR19","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","volume":"371","author":"JC Byrd","year":"2014","unstructured":"Byrd JC, Brown JR, O\u2019Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P (2014) Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 371(3):213\u2013223","journal-title":"N Engl J Med"},{"issue":"16","key":"7_CR20","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","volume":"125","author":"JC Byrd","year":"2015","unstructured":"Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Shaw Y, Bilotti E, Zhou C, James DF, O\u2019Brien S (2015) Three-year follow-up of treatment-na\u00efve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood 125(16):2497\u20132506","journal-title":"Blood"},{"issue":"5","key":"7_CR21","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/bjh.13200","volume":"168","author":"Y Cao","year":"2015","unstructured":"Cao Y, Hunter ZR, Liu X, Xu L, Yang G, Chen J, Tsakmaklis N, Kanan S, Castillo JJ, Treon SP (2015) CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P)-directed survival signalling in Waldenstrom macroglobulinaemia cells. Br J Haematol 168(5):701\u2013707","journal-title":"Br J Haematol"},{"issue":"2","key":"7_CR22","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(15)00465-9","volume":"17","author":"A Chanan-Khan","year":"2016","unstructured":"Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, Dilhuydy M-S, Pylypenko H, Loscertales J, Avigdor A, Rule S, Villa D, Samoilova O, Panagiotidis P, Goy A, Mato A, Pavlovsky MA, Karlsson C, Mahler M, Salman M, Sun S, Phelps C, Balasubramanian S, Howes A, Hallek M (2016) Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol 17(2):200\u2013211","journal-title":"Lancet Oncol"},{"issue":"4","key":"7_CR23","doi-asserted-by":"crossref","first-page":"R115","DOI":"10.1186\/ar3400","volume":"13","author":"BY Chang","year":"2011","unstructured":"Chang BY, Huang MM, Francesco M, Chen J, Sokolove J, Magadala P, Robinson WH, Buggy JJ (2011) The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther 13(4):R115","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"7_CR24","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1158\/1535-7163.MCT-15-0923","volume":"15","author":"J Chen","year":"2016","unstructured":"Chen J, Kinoshita T, Sukbuntherng J, Chang BY, Elias L (2016a) Ibrutinib inhibits ERBB receptor tyrosine kinases and HER2-amplified breast cancer cell growth. Mol Cancer Ther 15(12):2835\u20132844","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"7_CR25","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/leu.2015.316","volume":"30","author":"SS Chen","year":"2016","unstructured":"Chen SS, Chang BY, Chang S, Tong T, Ham S, Sherry B, Burger JA, Rai KR, Chiorazzi N (2016b) BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia. Leukemia 30(4):833\u2013843","journal-title":"Leukemia"},{"issue":"8","key":"7_CR26","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1056\/NEJMra041720","volume":"352","author":"N Chiorazzi","year":"2005","unstructured":"Chiorazzi N, Rai KR, Ferrarini M (2005) Chronic lymphocytic leukemia. N Engl J Med 352(8):804\u2013815","journal-title":"N Engl J Med"},{"issue":"9","key":"7_CR27","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","volume":"4","author":"D Chiron","year":"2014","unstructured":"Chiron D, Di Liberto M, Martin P, Huang X, Sharman J, Blecua P, Mathew S, Vijay P, Eng K, Ali S, Johnson A, Chang B, Ely S, Elemento O, Mason CE, Leonard JP, Chen-Kiang S (2014) Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer Discov 4(9):1022\u20131035","journal-title":"Cancer Discov"},{"issue":"1","key":"7_CR28","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/bjh.12206","volume":"161","author":"G Dasmahapatra","year":"2013","unstructured":"Dasmahapatra G, Patel H, Dent P, Fisher RI, Friedberg J, Grant S (2013) The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib. Br J Haematol 161(1):43\u201356","journal-title":"Br J Haematol"},{"issue":"22","key":"7_CR29","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1182\/blood.V128.22.3243.3243","volume":"128","author":"MS Davids","year":"2016","unstructured":"Davids MS, Kim HT, Brander DM, Bsat J, Savell A, Francoeur K, Hellman J, Jacobson CA, Hochberg E, Takvorian R, Abramson JS, Fisher DC, Brown JR (2016) Initial results of a multicenter, phase II study of ibrutinib plus fcr (iFCR) as frontline therapy for younger CLL patients. Blood 128(22):3243","journal-title":"Blood"},{"issue":"7277","key":"7_CR30","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","volume":"463","author":"RE Davis","year":"2010","unstructured":"Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL, Wright G, Xiao W, Powell J, Jiang JK, Thomas CJ, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Johnson NA, Rimsza LM, Campo E, Jaffe ES, Wilson WH, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pierce SK, Staudt LM (2010) Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463(7277):88\u201392","journal-title":"Nature"},{"issue":"1","key":"7_CR31","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.immuni.2006.11.012","volume":"26","author":"DJ Gorter de","year":"2007","unstructured":"de Gorter DJ, Beuling EA, Kersseboom R, Middendorp S, van Gils JM, Hendriks RW, Pals ST, Spaargaren M (2007) Bruton\u2019s tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing. Immunity 26(1):93\u2013104","journal-title":"Immunity"},{"issue":"4","key":"7_CR32","doi-asserted-by":"crossref","first-page":"e00156","DOI":"10.1002\/prp2.156","volume":"3","author":"J Jong de","year":"2015","unstructured":"de Jong J, Skee D, Murphy J, Sukbuntherng J, Hellemans P, Smit J, de Vries R, Jiao JJ, Snoeys J, Mannaert E (2015a) Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants. Pharmacol Res Perspect 3(4):e00156","journal-title":"Pharmacol Res Perspect"},{"issue":"5","key":"7_CR33","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00280-015-2708-9","volume":"75","author":"J Jong de","year":"2015","unstructured":"de Jong J, Sukbuntherng J, Skee D, Murphy J, O\u2019Brien S, Byrd JC, James D, Hellemans P, Loury DJ, Jiao J, Chauhan V, Mannaert E (2015b) The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia. Cancer Chemother Pharmacol 75(5):907\u2013916","journal-title":"Cancer Chemother Pharmacol"},{"issue":"22","key":"7_CR34","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1182\/blood.V128.22.1588.1588","volume":"128","author":"J Jong de","year":"2016","unstructured":"de Jong J, Hellemans P, Jiao J, Sukbuntherng J, Ouellet D (2016) An open-label, sequential-design drug interaction study of the effects of omeprazole on the pharmacokinetics of ibrutinib in healthy adults. Blood 128(22):1588","journal-title":"Blood"},{"issue":"11","key":"7_CR35","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1182\/blood-2011-11-390989","volume":"119","author":"MFM Rooij de","year":"2012","unstructured":"de Rooij MFM, Kuil A, Geest CR, Eldering E, Chang BY, Buggy JJ, Pals ST, Spaargaren M (2012) The clinically active BTK inhibitor PCI-32765 targets B-cell receptor\u2014and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 119(11):2590\u20132594","journal-title":"Blood"},{"issue":"5","key":"7_CR36","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/cpt.419","volume":"100","author":"L Zwart de","year":"2016","unstructured":"de Zwart L, Snoeys J, De Jong J, Sukbuntherng J, Mannaert E, Monshouwer M (2016) Ibrutinib dosing strategies based on interaction potential of CYP3A4 perpetrators using physiologically based pharmacokinetic modeling. Clin Pharmacol Ther 100(5):548\u2013557","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"7_CR37","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nchembio.481","volume":"7","author":"JA Paolo Di","year":"2011","unstructured":"Di Paolo JA, Huang T, Balazs M, Barbosa J, Barck KH, Bravo BJ, Carano RA, Darrow J, Davies DR, DeForge LE, Diehl L, Ferrando R, Gallion SL, Giannetti AM, Gribling P, Hurez V, Hymowitz SG, Jones R, Kropf JE, Lee WP, Maciejewski PM, Mitchell SA, Rong H, Staker BL, Whitney JA, Yeh S, Young WB, Yu C, Zhang J, Reif K, Currie KS (2011) Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat Chem Biol 7(1):41\u201350","journal-title":"Nat Chem Biol"},{"issue":"23","key":"7_CR38","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood.V126.23.2745.2745","volume":"126","author":"MA Dimopoulos","year":"2015","unstructured":"Dimopoulos MA, Trotman J, Tedeschi A, Matous JV, Macdonald D, Tam C, Tournilhac O, Ma S, Oriol A, Heffner LT, Shustik C, Garc\u00eda-Sanz R, Cornell RF, Fern\u00e1ndez de Larrea C, Castillo JJ, Granell M, Kyrtsonis M-C, Leblond V, Symeonidis A, Singh P, Li J, Graef T, Bilotti E, Treon S, Buske C (2015) Ibrutinib therapy in rituximab-refractory patients with Waldenstr\u00f6m\u2019s macroglobulinemia: initial results from an international, multicenter, open-label phase 3 substudy (iNNOVATE). Blood 126(23):2745","journal-title":"Blood"},{"issue":"26","key":"7_CR39","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","volume":"343","author":"H D\u00f6hner","year":"2000","unstructured":"D\u00f6hner H, Stilgenbauer S, Benner A, Leupolt E, Kr\u00f6ber A, Bullinger L, D\u00f6hner K, Bentz M, Lichter P (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343(26):1910\u20131916","journal-title":"N Engl J Med"},{"issue":"10020","key":"7_CR40","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","volume":"387","author":"M Dreyling","year":"2016","unstructured":"Dreyling M, Jurczak W, Jerkeman M, Silva RS, Rusconi C, Trneny M, Offner F, Caballero D, Joao C, Witzens-Harig M, Hess G, Bence-Bruckler I, Cho SG, Bothos J, Goldberg JD, Enny C, Traina S, Balasubramanian S, Bandyopadhyay N, Sun S, Vermeulen J, Rizo A, Rule S (2016) Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet 387(10020):770\u2013778","journal-title":"Lancet"},{"issue":"15","key":"7_CR41","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","volume":"122","author":"JA Dubovsky","year":"2013","unstructured":"Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, Hessler JD, Liu TM, Chang BY, Larkin KM, Stefanovski MR, Chappell DL, Frissora FW, Smith LL, Smucker KA, Flynn JM, Jones JA, Andritsos LA, Maddocks K, Lehman AM, Furman R, Sharman J, Mishra A, Caligiuri MA, Satoskar AR, Buggy JJ, Muthusamy N, Johnson AJ, Byrd JC (2013a) Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 122(15):2539\u20132549","journal-title":"Blood"},{"issue":"19","key":"7_CR42","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1182\/blood-2013-05-504597","volume":"122","author":"JA Dubovsky","year":"2013","unstructured":"Dubovsky JA, Chappell DL, Harrington BK, Agrawal K, Andritsos LA, Flynn JM, Jones JA, Paulaitis ME, Bolon B, Johnson AJ, Byrd JC, Muthusamy N (2013b) Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing. Blood 122(19):3308\u20133316","journal-title":"Blood"},{"issue":"1","key":"7_CR43","doi-asserted-by":"crossref","first-page":"192","DOI":"10.4161\/19420862.2015.989020","volume":"7","author":"MN Duong","year":"2015","unstructured":"Duong MN, Matera EL, Mathe D, Evesque A, Valsesia-Wittmann S, Clemenceau B, Dumontet C (2015) Effect of kinase inhibitors on the therapeutic properties of monoclonal antibodies. MAbs 7(1):192\u2013198","journal-title":"MAbs"},{"issue":"1","key":"7_CR44","doi-asserted-by":"crossref","first-page":"e2016011","DOI":"10.4084\/mjhid.2016.011","volume":"8","author":"L Falchi","year":"2016","unstructured":"Falchi L, Baron JM, Orlikowski CA, Ferrajoli A (2016) BCR signaling inhibitors: an overview of toxicities associated with ibrutinib and idelalisib in patients with chronic lymphocytic leukemia. Mediterr J Hematol Infect Dis 8(1):e2016011","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"23","key":"7_CR45","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1182\/blood.V126.23.2933.2933","volume":"126","author":"M Farooqui","year":"2015","unstructured":"Farooqui M, Valdez J, Soto S, Bray A, Tian X, Wiestner A (2015a) Atrial fibrillation in CLL\/SLL patients on ibrutinib. Blood 126(23):2933","journal-title":"Blood"},{"issue":"23","key":"7_CR46","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1182\/blood.V126.23.2937.2937","volume":"126","author":"M Farooqui","year":"2015","unstructured":"Farooqui M, Valdez J, Soto S, Stetler-Stevenson M, Yuan CM, Thomas F, Tian X, Maric I, Wiestner A (2015b) Single agent ibrutinib in CLL\/SLL patients with and without deletion 17p. Blood 126(23):2937","journal-title":"Blood"},{"issue":"2","key":"7_CR47","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1470-2045(14)71182-9","volume":"16","author":"MZH Farooqui","year":"2015","unstructured":"Farooqui MZH, Valdez J, Martyr S, Aue G, Saba N, Niemann CU, Herman SEM, Tian X, Marti G, Soto S, Hughes TE, Jones J, Lipsky A, Pittaluga S, Stetler-Stevenson M, Yuan C, Lee YS, Pedersen LB, Geisler CH, Calvo KR, Arthur DC, Maric I, Childs R, Young NS, Wiestner A (2015c) Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol 16(2):169\u2013176","journal-title":"Lancet Oncol"},{"issue":"2","key":"7_CR48","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","volume":"127","author":"K Fischer","year":"2016","unstructured":"Fischer K, Bahlo J, Fink AM, Goede V, Herling CD, Cramer P, Langerbeins P, von Tresckow J, Engelke A, Maurer C, Kovacs G, Herling M, Tausch E, Kreuzer K-A, Eichhorst B, B\u00f6ttcher S, Seymour JF, Ghia P, Marlton P, Kneba M, Wendtner C-M, D\u00f6hner H, Stilgenbauer S, Hallek M (2016) Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood 127(2):208\u2013215","journal-title":"Blood"},{"key":"7_CR49","doi-asserted-by":"crossref","unstructured":"Gashonia LM, Carver JR, O\u2019Quinn R, Clasen S, Hughes ME, Schuster SJ, Isaac K, Kennard K, Svoboda J, Daniel C, Tsai DE, Fanning MJ, Nasta S, Landsburg DJ, Nabhan C, Mato AR (2017) Persistence of ibrutinib-associated hypertension in CLL pts treated in a real-world experience. J Clin Oncol 35(15_suppl):7525\u20137525","DOI":"10.1200\/JCO.2017.35.15_suppl.7525"},{"key":"7_CR50","doi-asserted-by":"crossref","unstructured":"Gill S, Frey NV, Hexner EO, Lacey SF, Melenhorst JJ, Byrd JC, Metzger S, Marcus T, Gladney W, Marcucci K, Hwang W-T, June CH, Porter DL (2017) CD19 CAR-T cells combined with ibrutinib to induce complete remission in CLL. J Clin Oncol 35(15_suppl):7509\u20137509","DOI":"10.1200\/JCO.2017.35.15_suppl.7509"},{"issue":"12","key":"7_CR51","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","volume":"370","author":"V Goede","year":"2014","unstructured":"Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy M-S, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer K-A, Stilgenbauer S, D\u00f6hner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M (2014) Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370(12):1101\u20131110","journal-title":"N Engl J Med"},{"issue":"6","key":"7_CR52","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1007\/s10637-014-0141-2","volume":"32","author":"N Grabinski","year":"2014","unstructured":"Grabinski N, Ewald F (2014) Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells. Invest New Drugs 32(6):1096\u20131104","journal-title":"Invest New Drugs"},{"issue":"9","key":"7_CR53","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","volume":"7","author":"C Grommes","year":"2017","unstructured":"Grommes C, Pastore A, Palaskas N, Tang SS, Campos C, Schartz D, Codega P, Nichol D, Clark O, Hsieh WY, Rohle D, Rosenblum M, Viale A, Tabar VS, Brennan CW, Gavrilovic IT, Kaley TJ, Nolan CP, Omuro A, Pentsova E, Thomas AA, Tsyvkin E, Noy A, Palomba ML, Hamlin P, Sauter CS, Moskowitz CH, Wolfe J, Dogan A, Won M, Glass J, Peak S, Lallana EC, Hatzoglou V, Reiner AS, Gutin PH, Huse JT, Panageas KS, Graeber TG, Schultz N, DeAngelis LM, Mellinghoff IK (2017) Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma. Cancer Discov 7(9):1018\u20131029","journal-title":"Cancer Discov"},{"issue":"3","key":"7_CR54","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1158\/2159-8290.CD-15-0827","volume":"6","author":"AJ Gunderson","year":"2016","unstructured":"Gunderson AJ, Kaneda MM, Tsujikawa T, Nguyen AV, Affara NI, Ruffell B, Gorjestani S, Liudahl SM, Truitt M, Olson P, Kim G, Hanahan D, Tempero MA, Sheppard B, Irving B, Chang BY, Varner JA, Coussens LM (2016) Bruton tyrosine kinase-dependent immune cell cross-talk drives pancreas cancer. Cancer Discov 6(3):270\u2013285","journal-title":"Cancer Discov"},{"issue":"4","key":"7_CR55","doi-asserted-by":"crossref","first-page":"4598","DOI":"10.18632\/oncotarget.6727","volume":"7","author":"A Guo","year":"2016","unstructured":"Guo A, Lu P, Galanina N, Nabhan C, Smith SM, Coleman M, Wang YL (2016a) Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib. Oncotarget 7(4):4598\u20134610","journal-title":"Oncotarget"},{"issue":"22","key":"7_CR56","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1182\/blood.V128.22.1838.1838","volume":"128","author":"H Guo","year":"2016","unstructured":"Guo H, Huang S, Liu Y, Li CJ, Wang J, Zhang V, Ahmed M, Lam LT, Zhang H, Nomie K, Zhang L, Wang M (2016b) Genetic and molecular characterization of ibrutinib-resistant mantle cell lymphoma: designing innovative therapeutic strategies. Blood 128(22):1838","journal-title":"Blood"},{"issue":"12","key":"7_CR57","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"M Hallek","year":"2008","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, D\u00f6hner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111(12):5446\u20135456","journal-title":"Blood"},{"key":"7_CR58","doi-asserted-by":"crossref","unstructured":"Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Gr\u00fcnhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, J\u00e4ger U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, B\u00fchler A, Winkler D, Zenz T, B\u00f6ttcher S, Ritgen M, Mendila M, Kneba M, D\u00f6hner H, Stilgenbauer S (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376(9747):1164\u20131174","DOI":"10.1016\/S0140-6736(10)61381-5"},{"issue":"4","key":"7_CR59","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrc3702","volume":"14","author":"RW Hendriks","year":"2014","unstructured":"Hendriks RW, Yuvaraj S, Kil LP (2014) Targeting Bruton\u2019s tyrosine kinase in B cell malignancies. Nat Rev Cancer 14(4):219\u2013232","journal-title":"Nat Rev Cancer"},{"issue":"23","key":"7_CR60","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","volume":"117","author":"SEM Herman","year":"2011","unstructured":"Herman SEM, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, Flynn J, Jones J, Blum KA, Buggy JJ, Hamdy A, Johnson AJ, Byrd JC (2011) Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 117(23):6287\u20136296","journal-title":"Blood"},{"issue":"20","key":"7_CR61","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1158\/1078-0432.CCR-15-0781","volume":"21","author":"SE Herman","year":"2015","unstructured":"Herman SE, Mustafa RZ, Jones J, Wong DH, Farooqui M, Wiestner A (2015) Treatment with ibrutinib inhibits BTK- and VLA-4-dependent adhesion of chronic lymphocytic leukemia cells in vivo. Clin Cancer Res 21(20):4642\u20134651","journal-title":"Clin Cancer Res"},{"issue":"35","key":"7_CR62","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1200\/JCO.2007.12.9098","volume":"25","author":"P Hillmen","year":"2007","unstructured":"Hillmen P, Skotnicki AB, Robak T, Jaksic B, Dmoszynska A, Wu J, Sirard C, Mayer J (2007) Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 25(35):5616\u20135623","journal-title":"J Clin Oncol"},{"issue":"29","key":"7_CR63","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","volume":"107","author":"LA Honigberg","year":"2010","unstructured":"Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, Li S, Pan Z, Thamm DH, Miller RA, Buggy JJ (2010) The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 107(29):13075\u201313080","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"7_CR64","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1182\/blood-2014-12-617522","volume":"126","author":"SM Jaglowski","year":"2015","unstructured":"Jaglowski SM, Jones JA, Nagar V, Flynn JM, Andritsos LA, Maddocks KJ, Woyach JA, Blum KA, Grever MR, Smucker K, Ruppert AS, Heerema NA, Lozanski G, Stefanos M, Munneke B, West J-S, Neuenburg JK, James DF, Hall N, Johnson AJ, Byrd JC (2015) Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b\/2 study. Blood 126(7):842\u2013850","journal-title":"Blood"},{"issue":"13","key":"7_CR65","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2014-09-603670","volume":"125","author":"P Jain","year":"2015","unstructured":"Jain P, Keating M, Wierda W, Estrov Z, Ferrajoli A, Jain N, George B, James D, Kantarjian H, Burger J, O\u2019Brien S (2015) Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood 125(13):2062\u20132067","journal-title":"Blood"},{"issue":"22","key":"7_CR66","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1182\/blood.V128.22.148.148","volume":"128","author":"M Jerkeman","year":"2016","unstructured":"Jerkeman M, Hutchings M, R\u00e4ty R, Wader KF, Laurell A, Kuitunen H, Toldbod H, Pedersen LB, Eskelund CW, Gr\u00f8nb\u00e6k K, Niemann CU, Geisler CH, Kolstad A (2016) Ibrutinib-lenalidomide-rituximab in patients with relapsed\/refractory mantle cell lymphoma: first results from the Nordic Lymphoma Group MCL6 (PHILEMON) phase II trial. Blood 128(22):148","journal-title":"Blood"},{"issue":"4","key":"7_CR67","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/leu.2014.247","volume":"29","author":"S Kamel","year":"2015","unstructured":"Kamel S, Horton L, Ysebaert L, Levade M, Burbury K, Tan S, Cole-Sinclair M, Reynolds J, Filshie R, Schischka S, Khot A, Sandhu S, Keating MJ, Nandurkar H, Tam CS (2015) Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia 29(4):783\u2013787","journal-title":"Leukemia"},{"issue":"12","key":"7_CR68","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1182\/blood-2014-01-547869","volume":"123","author":"HE Kohrt","year":"2014","unstructured":"Kohrt HE, Sagiv-Barfi I, Rafiq S, Herman SEM, Butchar JP, Cheney C, Zhang X, Buggy JJ, Muthusamy N, Levy R, Johnson AJ, Byrd JC (2014) Ibrutinib antagonizes rituximab-dependent NK cell\u2013mediated cytotoxicity. Blood 123(12):1957\u20131960","journal-title":"Blood"},{"issue":"11","key":"7_CR69","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1080\/15384047.2015.1078023","volume":"16","author":"L Kokabee","year":"2015","unstructured":"Kokabee L, Wang X, Sevinsky CJ, Wang WL, Cheu L, Chittur SV, Karimipoor M, Tenniswood M, Conklin DS (2015) Bruton\u2019s tyrosine kinase is a potential therapeutic target in prostate cancer. Cancer Biol Ther 16(11):1604\u20131615","journal-title":"Cancer Biol Ther"},{"key":"7_CR70","doi-asserted-by":"crossref","unstructured":"Kondo K, Shaim H, Thompson PA, Burger JA, Keating M, Estrov Z, Harris D, Kim E, Ferrajoli A, Daher M, Basar R, Muftuoglu M, Imahashi N, Alsuliman A, Sobieski C, Gokdemir E, Wierda W, Jain N, Liu E, Shpall EJ, Rezvani K (2017) Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1\/PD-L1 pathway. Leukemia","DOI":"10.1038\/leu.2017.304"},{"key":"7_CR71","doi-asserted-by":"crossref","unstructured":"Leong DP, Caron F, Hillis C, Duan A, Healey JS, Fraser G, Siegal D (2016) The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. Blood","DOI":"10.1182\/blood-2016-05-712828"},{"issue":"26","key":"7_CR72","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1182\/blood-2014-06-583294","volume":"124","author":"M Levade","year":"2014","unstructured":"Levade M, David E, Garcia C, Laurent PA, Cadot S, Michallet AS, Bordet JC, Tam C, Sie P, Ysebaert L, Payrastre B (2014) Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood 124(26):3991\u20133995","journal-title":"Blood"},{"issue":"6","key":"7_CR73","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/bjh.12974","volume":"166","author":"J Ma","year":"2014","unstructured":"Ma J, Lu P, Guo A, Cheng S, Zong H, Martin P, Coleman M, Wang YL (2014) Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells. Br J Haematol 166(6):849\u2013861","journal-title":"Br J Haematol"},{"issue":"2","key":"7_CR74","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1182\/blood-2014-08-597914","volume":"125","author":"K Maddocks","year":"2015","unstructured":"Maddocks K, Christian B, Jaglowski S, Flynn J, Jones JA, Porcu P, Wei L, Jenkins C, Lozanski G, Byrd JC, Blum KA (2015a) A phase 1\/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed\/refractory non-hodgkin lymphoma. Blood 125(2):242\u2013248","journal-title":"Blood"},{"issue":"1","key":"7_CR75","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","volume":"1","author":"KJ Maddocks","year":"2015","unstructured":"Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, Lozanski A, Davis M, Gordon A, Smith LL, Mantel R, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Awan F, Blum KA, Grever MR, Johnson AJ, Byrd JC, Woyach JA (2015b) Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol 1(1):80\u201387","journal-title":"JAMA Oncol"},{"issue":"8","key":"7_CR76","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1158\/0008-5472.CAN-14-2852","volume":"75","author":"D Masso-Valles","year":"2015","unstructured":"Masso-Valles D, Jauset T, Serrano E, Sodir NM, Pedersen K, Affara NI, Whitfield JR, Beaulieu ME, Evan GI, Elias L, Arribas J, Soucek L (2015) Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma. Cancer Res 75(8):1675\u20131681","journal-title":"Cancer Res"},{"issue":"2","key":"7_CR77","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1073\/pnas.0606663104","volume":"104","author":"JR McMullen","year":"2007","unstructured":"McMullen JR, Amirahmadi F, Woodcock EA, Schinke-Braun M, Bouwman RD, Hewitt KA, Mollica JP, Zhang L, Zhang Y, Shioi T, Buerger A, Izumo S, Jay PY, Jennings GL (2007) Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy. Proc Natl Acad Sci USA 104(2):612\u2013617","journal-title":"Proc Natl Acad Sci USA"},{"issue":"25","key":"7_CR78","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","volume":"124","author":"JR McMullen","year":"2014","unstructured":"McMullen JR, Boey EJ, Ooi JY, Seymour JF, Keating MJ, Tam CS (2014) Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood 124(25):3829\u20133830","journal-title":"Blood"},{"issue":"5","key":"7_CR79","first-page":"420","volume":"6","author":"GA McNally","year":"2015","unstructured":"McNally GA, Long JM, Brophy LR, Badillo MR (2015) Ibrutinib: implications for use in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia. J Adv Pract Oncol 6(5):420\u2013431","journal-title":"J Adv Pract Oncol"},{"key":"7_CR80","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nature11309","volume":"489","author":"MD-V Minden","year":"2012","unstructured":"Minden MD-V, \u00dcbelhart R, Schneider D, Wossning T, Bach MP, Buchner M, Hofmann D, Surova E, Follo M, K\u00f6hler F, Wardemann H, Zirlik K, Veelken H, Jumaa H (2012) Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature 489:309","journal-title":"Nature"},{"issue":"1","key":"7_CR81","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1600-065X.2008.00741.x","volume":"228","author":"AJ Mohamed","year":"2009","unstructured":"Mohamed AJ, Yu L, Backesjo CM, Vargas L, Faryal R, Aints A, Christensson B, Berglof A, Vihinen M, Nore BF, Smith CI (2009) Bruton\u2019s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol Rev 228(1):58\u201373","journal-title":"Immunol Rev"},{"issue":"45","key":"7_CR82","doi-asserted-by":"crossref","first-page":"73558","DOI":"10.18632\/oncotarget.12434","volume":"7","author":"A Mohanty","year":"2016","unstructured":"Mohanty A, Sandoval N, Das M, Pillai R, Chen L, Chen RW, Amin HM, Wang M, Marcucci G, Weisenburger DD, Rosen ST, Pham LV, Ngo VN (2016) CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma. Oncotarget 7(45):73558\u201373572","journal-title":"Oncotarget"},{"issue":"14","key":"7_CR83","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1080\/15384101.2014.998067","volume":"14","author":"MY Murray","year":"2015","unstructured":"Murray MY, Zaitseva L, Auger MJ, Craig JI, MacEwan DJ, Rushworth SA, Bowles KM (2015) Ibrutinib inhibits BTK-driven NF-kappaB p65 activity to overcome bortezomib-resistance in multiple myeloma. Cell Cycle 14(14):2367\u20132375","journal-title":"Cell Cycle"},{"issue":"16","key":"7_CR84","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","volume":"129","author":"A Noy","year":"2017","unstructured":"Noy A, de Vos S, Thieblemont C, Martin P, Flowers CR, Morschhauser F, Collins GP, Ma S, Coleman M, Peles S, Smith S, Barrientos JC, Smith A, Munneke B, Dimery I, Beaupre DM, Chen R (2017) Targeting Bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma. Blood 129(16):2224\u20132232","journal-title":"Blood"},{"key":"7_CR85","doi-asserted-by":"crossref","unstructured":"O\u2019Brien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA, Grant B, Richards DA, Coleman M, Wierda WG (2014) Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b\/2 trial. Lancet Oncol 15","DOI":"10.1016\/S1470-2045(13)70513-8"},{"issue":"10","key":"7_CR86","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1470-2045(16)30212-1","volume":"17","author":"S O\u2019Brien","year":"2016","unstructured":"O\u2019Brien S, Jones JA, Coutre SE, Mato AR, Hillmen P, Tam C, Osterborg A, Siddiqi T, Thirman MJ, Furman RR, Ilhan O, Keating MJ, Call TG, Brown JR, Stevens-Brogan M, Li Y, Clow F, James DF, Chu AD, Hallek M, Stilgenbauer S (2016a) Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol 17(10):1409\u20131418","journal-title":"Lancet Oncol"},{"issue":"22","key":"7_CR87","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/blood.V128.22.233.233","volume":"128","author":"SM O\u2019Brien","year":"2016","unstructured":"O\u2019Brien SM, Furman RR, Coutre SE, Flinn IW, Burger J, Blum K, Sharman J, Wierda WG, Jones J, Zhao W, Heerema NA, Johnson AJ, Luan Y, James DF, Chu AD, Byrd JC (2016b) Five-year experience with single-agent ibrutinib in patients with previously untreated and relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic leukemia. Blood 128(22):233","journal-title":"Blood"},{"issue":"5","key":"7_CR88","first-page":"1663","volume":"95","author":"A Oda","year":"2000","unstructured":"Oda A, Ikeda Y, Ochs HD, Druker BJ, Ozaki K, Handa M, Ariga T, Sakiyama Y, Witte ON, Wahl MI (2000) Rapid tyrosine phosphorylation and activation of Bruton\u2019s tyrosine\/Tec kinases in platelets induced by collagen binding or CD32 cross-linking. Blood 95(5):1663\u20131670","journal-title":"Blood"},{"key":"7_CR89","first-page":"4642831","volume":"2016","author":"K Okamoto","year":"2016","unstructured":"Okamoto K, Proia LA, Demarais PL (2016) Disseminated cryptococcal disease in a patient with chronic lymphocytic leukemia on ibrutinib. Case Rep Infect Dis 2016:4642831","journal-title":"Case Rep Infect Dis"},{"issue":"5","key":"7_CR90","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1002\/eji.200535799","volume":"36","author":"S Ortolano","year":"2006","unstructured":"Ortolano S, Hwang IY, Han SB, Kehrl JH (2006) Roles for phosphoinositide 3-kinases, Bruton\u2019s tyrosine kinase, and Jun kinases in B lymphocyte chemotaxis and homing. Eur J Immunol 36(5):1285\u20131295","journal-title":"Eur J Immunol"},{"issue":"1","key":"7_CR91","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/cmdc.200600221","volume":"2","author":"Z Pan","year":"2007","unstructured":"Pan Z, Scheerens H, Li S-J, Schultz BE, Sprengeler PA, Burrill LC, Mendonca RV, Sweeney MD, Scott KCK, Grothaus PG, Jeffery DA, Spoerke JM, Honigberg LA, Young PR, Dalrymple SA, Palmer JT (2007) Discovery of selective irreversible inhibitors for Bruton\u2019s tyrosine kinase. ChemMedChem 2(1):58\u201361","journal-title":"ChemMedChem"},{"issue":"12","key":"7_CR92","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1182\/blood-2016-04-709519","volume":"128","author":"G Pavlasova","year":"2016","unstructured":"Pavlasova G, Borsky M, Seda V, Cerna K, Osickova J, Doubek M, Mayer J, Calogero R, Trbusek M, Pospisilova S, Davids MS, Kipps TJ, Brown JR, Mraz M (2016) Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4\/SDF-1 axis. Blood 128(12):1609\u20131613","journal-title":"Blood"},{"issue":"24","key":"7_CR93","doi-asserted-by":"crossref","first-page":"39218","DOI":"10.18632\/oncotarget.16836","volume":"8","author":"L Ping","year":"2017","unstructured":"Ping L, Ding N, Shi Y, Feng L, Li J, Liu Y, Lin Y, Shi C, Wang X, Pan Z, Song Y, Zhu J (2017) The Bruton\u2019s tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages. Oncotarget 8(24):39218\u201339229","journal-title":"Oncotarget"},{"issue":"5","key":"7_CR94","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1182\/blood-2011-10-386417","volume":"119","author":"S Ponader","year":"2012","unstructured":"Ponader S, Chen S-S, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, Keating MJ, O\u2019Brien S, Chiorazzi N, Burger JA (2012) The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 119(5):1182\u20131189","journal-title":"Blood"},{"issue":"1","key":"7_CR95","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm.3435","volume":"20","author":"R Rahal","year":"2014","unstructured":"Rahal R, Frick M, Romero R, Korn JM, Kridel R, Chan FC, Meissner B, Bhang HE, Ruddy D, Kauffmann A, Farsidjani A, Derti A, Rakiec D, Naylor T, Pfister E, Kovats S, Kim S, Dietze K, Dorken B, Steidl C, Tzankov A, Hummel M, Monahan J, Morrissey MP, Fritsch C, Sellers WR, Cooke VG, Gascoyne RD, Lenz G, Stegmeier F (2014) Pharmacological and genomic profiling identifies NF-kappaB-targeted treatment strategies for mantle cell lymphoma. Nat Med 20(1):87\u201392","journal-title":"Nat Med"},{"issue":"1","key":"7_CR96","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.cellsig.2012.09.008","volume":"25","author":"SA Rushworth","year":"2013","unstructured":"Rushworth SA, Bowles KM, Barrera LN, Murray MY, Zaitseva L, MacEwan DJ (2013) BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-kappaB. Cell Signal 25(1):106\u2013112","journal-title":"Cell Signal"},{"issue":"9","key":"7_CR97","doi-asserted-by":"crossref","first-page":"E966","DOI":"10.1073\/pnas.1500712112","volume":"112","author":"I Sagiv-Barfi","year":"2015","unstructured":"Sagiv-Barfi I, Kohrt HEK, Czerwinski DK, Ng PP, Chang BY, Levy R (2015) Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proc Natl Acad Sci 112(9):E966\u2013E972","journal-title":"Proc Natl Acad Sci"},{"key":"7_CR98","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1600-065X.2000.imr017504.x","volume":"175","author":"AB Satterthwaite","year":"2000","unstructured":"Satterthwaite AB, Witte ON (2000) The role of Bruton\u2019s tyrosine kinase in B-cell development and function: a genetic perspective. Immunol Rev 175:120\u2013127","journal-title":"Immunol Rev"},{"issue":"10","key":"7_CR99","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/nri2172","volume":"7","author":"AM Scharenberg","year":"2007","unstructured":"Scharenberg AM, Humphries LA, Rawlings DJ (2007) Calcium signalling and cell-fate choice in B cells. Nat Rev Immunol 7(10):778\u2013789","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"7_CR100","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1124\/dmd.114.060061","volume":"43","author":"E Scheers","year":"2015","unstructured":"Scheers E, Leclercq L, de Jong J, Bode N, Bockx M, Laenen A, Cuyckens F, Skee D, Murphy J, Sukbuntherng J, Mannens G (2015) Absorption, metabolism, and excretion of oral 14C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. Drug Metab Dispos 43(2):289\u2013297","journal-title":"Drug Metab Dispos"},{"issue":"19","key":"7_CR101","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1182\/blood-2012-05-431783","volume":"120","author":"J Schwamb","year":"2012","unstructured":"Schwamb J, Feldhaus V, Baumann M, Patz M, Brodesser S, Brinker R, Claasen J, Pallasch CP, Hallek M, Wendtner C-M, Frenzel LP (2012) B-cell receptor triggers drug sensitivity of primary CLL cells by controlling glucosylation of ceramides. Blood 120(19):3978\u20133985","journal-title":"Blood"},{"issue":"3","key":"7_CR102","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/ejh.12427","volume":"94","author":"V Seda","year":"2015","unstructured":"Seda V, Mraz M (2015) B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells. Eur J Haematol 94(3):193\u2013205","journal-title":"Eur J Haematol"},{"issue":"12","key":"7_CR103","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1038\/leu.2014.126","volume":"28","author":"L Sehgal","year":"2014","unstructured":"Sehgal L, Mathur R, Braun FK, Wise JF, Berkova Z, Neelapu S, Kwak LW, Samaniego F (2014) FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphoma. Leukemia 28(12):2376\u20132387","journal-title":"Leukemia"},{"key":"7_CR104","doi-asserted-by":"crossref","unstructured":"Shao J, Markowitz JS, Bei D, An G (2014) Enzyme-transporter-mediated drug interactions with small molecule tyrosine kinase inhibitors. J Pharm Sci 103(12):3810\u20133833","DOI":"10.1002\/jps.24113"},{"issue":"12","key":"7_CR105","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.4049\/jimmunol.153.12.5607","volume":"153","author":"P Sideras","year":"1994","unstructured":"Sideras P, Muller S, Shiels H, Jin H, Khan WN, Nilsson L, Parkinson E, Thomas JD, Branden L, Larsson I et al (1994) Genomic organization of mouse and human Bruton\u2019s agammaglobulinemia tyrosine kinase (Btk) loci. J Immunol 153(12):5607\u20135617","journal-title":"J Immunol"},{"issue":"16","key":"7_CR106","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1182\/blood-2011-06-338855","volume":"118","author":"FK Stevenson","year":"2011","unstructured":"Stevenson FK, Krysov S, Davies AJ, Steele AJ, Packham G (2011) B-cell receptor signaling in chronic lymphocytic leukemia. Blood 118(16):4313\u20134320","journal-title":"Blood"},{"issue":"8","key":"7_CR107","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1158\/0008-5472.CAN-15-1490","volume":"76","author":"A Stiff","year":"2016","unstructured":"Stiff A, Trikha P, Wesolowski R, Kendra K, Hsu V, Uppati S, McMichael E, Duggan M, Campbell A, Keller K, Landi I, Zhong Y, Dubovsky J, Howard JH, Yu L, Harrington B, Old M, Reiff S, Mace T, Tridandapani S, Muthusamy N, Caligiuri MA, Byrd JC, Carson WE 3rd (2016) Myeloid-derived suppressor cells express Bruton\u2019s tyrosine kinase and can be depleted in tumor-bearing hosts by ibrutinib treatment. Cancer Res 76(8):2125\u20132136","journal-title":"Cancer Res"},{"issue":"9","key":"7_CR108","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1182\/blood-2011-12-396853","volume":"120","author":"Y-T Tai","year":"2012","unstructured":"Tai Y-T, Chang BY, Kong S-Y, Fulciniti M, Yang G, Calle Y, Hu Y, Lin J, Zhao J-J, Cagnetta A, Cea M, Sellitto MA, Zhong MY, Wang Q, Acharya C, Carrasco DR, Buggy JJ, Elias L, Treon SP, Matsui W, Richardson P, Munshi NC, Anderson KC (2012) Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood 120(9):1877\u20131887","journal-title":"Blood"},{"issue":"5","key":"7_CR109","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/bjh.13659","volume":"171","author":"K Takahashi","year":"2015","unstructured":"Takahashi K, Sivina M, Hoellenriegel J, Oki Y, Hagemeister FB, Fayad L, Romaguera JE, Fowler N, Fanale MA, Kwak LW, Samaniego F, Neelapu S, Xiao L, Huang X, Kantarjian H, Keating MJ, Wierda W, Fu K, Chan WC, Vose JM, O\u2019Brien S, Davis RE, Burger JA (2015) CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. Br J Haematol 171(5):726\u2013735","journal-title":"Br J Haematol"},{"issue":"3","key":"7_CR110","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/bjh.14324","volume":"175","author":"PA Thompson","year":"2016","unstructured":"Thompson PA, Levy V, Tam CS, Al Nawakil C, Goudot FX, Quinquenel A, Ysebaert L, Michallet AS, Dilhuydy MS, Van Den Neste E, Dupuis J, Keating MJ, Meune C, Cymbalista F (2016) Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study. Br J Haematol 175(3):462\u2013466","journal-title":"Br J Haematol"},{"issue":"15","key":"7_CR111","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","volume":"372","author":"SP Treon","year":"2015","unstructured":"Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, Argyropoulos KV, Yang G, Cao Y, Xu L, Patterson CJ, Rodig S, Zehnder JL, Aster JC, Harris NL, Kanan S, Ghobrial I, Castillo JJ, Laubach JP, Hunter ZR, Salman Z, Li J, Cheng M, Clow F, Graef T, Palomba ML, Advani RH (2015) Ibrutinib in previously treated Waldenstr\u00f6m\u2019s macroglobulinemia. N Engl J Med 372(15):1430\u20131440","journal-title":"N Engl J Med"},{"issue":"21","key":"7_CR112","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood.V124.21.31.31","volume":"124","author":"R Vij","year":"2014","unstructured":"Vij R, Huff CA, Bensinger WI, Siegel DS, Jagannath S, Berdeja J, Lendvai N, Lebovic D, Anderson LD, Costello CL, Stockerl-Goldstein KE, Laubach JP, Elias L, Clow F, Fardis M, Graef T, Bilotti E, Richardson PG (2014) Ibrutinib, single agent or in combination with dexamethasone, in patients with relapsed or relapsed\/refractory multiple myeloma (mm): preliminary phase 2 results. Blood 124(21):31","journal-title":"Blood"},{"key":"7_CR113","unstructured":"Vrontikis A, Carey J, Gilreath JA, Halwani A, Stephens DM, Sweetenham JW (2016) Proposed algorithm for managing ibrutinib-related atrial fibrillation. Oncology (Williston Park) 30(11):970\u2013974, 980-971, C973"},{"issue":"6","key":"7_CR114","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA (2013) Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369(6):507\u2013516","journal-title":"N Engl J Med"},{"issue":"6","key":"7_CR115","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","volume":"126","author":"ML Wang","year":"2015","unstructured":"Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Zhang L, Baher L, Cheng M, Lee D, Beaupre DM, Rule S (2015) Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood 126(6):739\u2013745","journal-title":"Blood"},{"issue":"22","key":"7_CR116","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1182\/blood.V128.22.147.147","volume":"128","author":"M Wang","year":"2016","unstructured":"Wang M, Lee HJ, Thirumurthi S, Chuang HH, Hagemeister FB, Westin JR, Fayad LE, Samaniego F, Turturro F, Chen W, Oriabure O, Huang SY, Li S, Zhang L, Badillo M, Hartig KH, Ahmed M, Nomie K, Lam LT, Addison AA, Romaguera JE (2016a) Chemotherapy-free induction with ibrutinib-rituximab followed by shortened cycles of chemo-immunotherapy consolidation in young, newly diagnosed mantle cell lymphoma patients: a phase II clinical trial. Blood 128(22):147","journal-title":"Blood"},{"issue":"1","key":"7_CR117","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(15)00438-6","volume":"17","author":"ML Wang","year":"2016","unstructured":"Wang ML, Lee H, Chuang H, Wagner-Bartak N, Hagemeister F, Westin J, Fayad L, Samaniego F, Turturro F, Oki Y, Chen W, Badillo M, Nomie K, DeLa Rosa M, Zhao D, Lam L, Addison A, Zhang H, Young KH, Li S, Santos D, Medeiros LJ, Champlin R, Romaguera J, Zhang L (2016b) Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol 17(1):48\u201356","journal-title":"Lancet Oncol"},{"issue":"1","key":"7_CR118","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13046-017-0549-6","volume":"36","author":"J Wang","year":"2017","unstructured":"Wang J, Liu X, Hong Y, Wang S, Chen P, Gu A, Guo X, Zhao P (2017) Ibrutinib, a Bruton\u2019s tyrosine kinase inhibitor, exhibits antitumoral activity and induces autophagy in glioblastoma. J Exp Clin Cancer Res 36(1):96","journal-title":"J Exp Clin Cancer Res"},{"issue":"43","key":"7_CR119","doi-asserted-by":"crossref","first-page":"69961","DOI":"10.18632\/oncotarget.11572","volume":"7","author":"L Wei","year":"2016","unstructured":"Wei L, Su YK, Lin CM, Chao TY, Huang SP, Huynh TT, Jan HJ, Whang-Peng J, Chiou JF, Wu AT, Hsiao M (2016) Preclinical investigation of ibrutinib, a Bruton\u2019s kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes. Oncotarget 7(43):69961\u201369975","journal-title":"Oncotarget"},{"issue":"8","key":"7_CR120","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","volume":"21","author":"WH Wilson","year":"2015","unstructured":"Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih C-J, Williams PM, Shaffer AL, Gerecitano J, de Vos S, Goy A, Kenkre VP, Barr PM, Blum KA, Shustov A, Advani R, Fowler NH, Vose JM, Elstrom RL, Habermann TM, Barrientos JC, McGreivy J, Fardis M, Chang BY, Clow F, Munneke B, Moussa D, Beaupre DM, Staudt LM (2015) Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 21(8):922\u2013926","journal-title":"Nat Med"},{"issue":"26","key":"7_CR121","doi-asserted-by":"crossref","first-page":"4132","DOI":"10.1182\/blood-2014-02-554220","volume":"123","author":"D Wodarz","year":"2014","unstructured":"Wodarz D, Garg N, Komarova NL, Benjamini O, Keating MJ, Wierda WG, Kantarjian H, James D, O\u2019Brien S, Burger JA (2014) Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib. Blood 123(26):4132\u20134135","journal-title":"Blood"},{"issue":"6","key":"7_CR122","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/blood-2012-02-362624","volume":"120","author":"JA Woyach","year":"2012","unstructured":"Woyach JA, Johnson AJ, Byrd JC (2012) The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood 120(6):1175\u20131184","journal-title":"Blood"},{"issue":"24","key":"7_CR123","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","volume":"370","author":"JA Woyach","year":"2014","unstructured":"Woyach JA, Furman RR, Liu T-M, Ozer HG, Zapatka M, Ruppert AS, Xue L, Li DH-H, Steggerda SM, Versele M, Dave SS, Zhang J, Yilmaz AS, Jaglowski SM, Blum KA, Lozanski A, Lozanski G, James DF, Barrientos JC, Lichter P, Stilgenbauer S, Buggy JJ, Chang BY, Johnson AJ, Byrd JC (2014a) Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib. N Engl J Med 370(24):2286\u20132294","journal-title":"N Engl J Med"},{"issue":"12","key":"7_CR124","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1182\/blood-2013-09-527853","volume":"123","author":"JA Woyach","year":"2014","unstructured":"Woyach JA, Smucker K, Smith LL, Lozanski A, Zhong Y, Ruppert AS, Lucas D, Williams K, Zhao W, Rassenti L, Ghia E, Kipps TJ, Mantel R, Jones J, Flynn J, Maddocks K, O\u2019Brien S, Furman RR, James DF, Clow F, Lozanski G, Johnson AJ, Byrd JC (2014b) Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood 123(12):1810\u20131817","journal-title":"Blood"},{"issue":"18","key":"7_CR125","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1182\/blood-2017-01-761726","volume":"129","author":"L Xu","year":"2017","unstructured":"Xu L, Tsakmaklis N, Yang G, Chen JG, Liu X, Demos M, Kofides A, Patterson CJ, Meid K, Gustine J, Dubeau T, Palomba ML, Advani R, Castillo JJ, Furman RR, Hunter ZR, Treon SP (2017) Acquired mutations associated with ibrutinib resistance in Waldenstr\u00f6m macroglobulinemia. Blood 129(18):2519\u20132525","journal-title":"Blood"},{"issue":"6","key":"7_CR126","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccr.2012.05.024","volume":"21","author":"Y Yang","year":"2012","unstructured":"Yang Y, Shaffer AL 3rd, Emre NC, Ceribelli M, Zhang M, Wright G, Xiao W, Powell J, Platig J, Kohlhammer H, Young RM, Zhao H, Yang Y, Xu W, Buggy JJ, Balasubramanian S, Mathews LA, Shinn P, Guha R, Ferrer M, Thomas C, Waldmann TA, Staudt LM (2012) Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 21(6):723\u2013737","journal-title":"Cancer Cell"},{"issue":"9","key":"7_CR127","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S1470-2045(14)70311-0","volume":"15","author":"A Younes","year":"2014","unstructured":"Younes A, Thieblemont C, Morschhauser F, Flinn I, Friedberg JW, Amorim S, Hivert B, Westin J, Vermeulen J, Bandyopadhyay N, de Vries R, Balasubramanian S, Hellemans P, Smit JW, Fourneau N, Oki Y (2014) Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Lancet Oncol 15(9):1019\u20131026","journal-title":"Lancet Oncol"},{"issue":"2","key":"7_CR128","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1053\/j.seminhematol.2015.01.008","volume":"52","author":"RM Young","year":"2015","unstructured":"Young RM, Shaffer AL 3rd, Phelan JD, Staudt LM (2015) B-cell receptor signaling in diffuse large B-cell lymphoma. Semin Hematol 52(2):77\u201385","journal-title":"Semin Hematol"},{"issue":"15","key":"7_CR129","doi-asserted-by":"crossref","first-page":"13255","DOI":"10.18632\/oncotarget.3658","volume":"6","author":"MA Zucha","year":"2015","unstructured":"Zucha MA, Wu AT, Lee WH, Wang LS, Lin WW, Yuan CC, Yeh CT (2015) Bruton\u2019s tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer. Oncotarget 6(15):13255\u201313268","journal-title":"Oncotarget"}],"container-title":["Recent Results in Cancer Research","Small Molecules in Hematology"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-319-91439-8_7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T23:32:18Z","timestamp":1693783938000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-319-91439-8_7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"ISBN":["9783319914381","9783319914398"],"references-count":129,"URL":"https:\/\/doi.org\/10.1007\/978-3-319-91439-8_7","relation":{},"ISSN":["0080-0015","2197-6767"],"issn-type":[{"value":"0080-0015","type":"print"},{"value":"2197-6767","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}